Compounds capable of modulating gpr65

Abstract

One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I). Wherein pring A is selected from: Y is CR10R10', wherein R10 and R10' are each independently selected from H, F, alkyl, and haloalkyl; Ra and Rb are each independently selected from H and alkyl; ring B is: a monocyclic aryl group; or a monocyclic heteroaryl group, each of which is substituted by: (i) a heteroaryl group substituted by at least one group selected from -NR15R16, and -O-(CH2)q-heterocycloalkyl, and optionally further substituted by one or more substituents selected from halo, alkyl, alkoxy, haloalkyl, haloalkoxy, CN, OH, SO2-alkyl, hydroxyalkyl, CO2R14, NR11R11', CONR12R12', alkyl-NR13R13', alkoxy-alkyl, alkoxy-alkoxy and NHSO2-alkyl; wherein said -(CH2)q-heterocycloalkyl group is further substituted by one or more substituents selected from CO2R14, halo, haloalkyl, haloalkoxy and alkyl; and (ii) optionally one or more substituents selected from halo, haloalkyl, haloalkoxy, alkyl and alkoxy; q is an integer from 0 to 3; R6 is selected from H and alkyl, more preferably H; R7, R8 and R9 are each independently selected from H, halo and alkyl; each R11, R11', R12, R12', R13 and R13' is independently selected from H, alkyl, and alkoxyalkyl; R14 is selected from alkyl and haloalkyl; R15 is selected from H and alkyl; and R16 is selected from alkyl, haloalkyl and CO-haloalkyl. Further aspects of the invention relate to compounds for use as a medicament, particularly in the field of immuno-oncology, immunology, and related applications.

Images